Skip to main content

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Completed · Phase 3 · NCT04987203

Conditions: Renal Cell Carcinoma

At a glance

Research payments reported, 2025
$1.6M
U.S. investigators named
39
Sites paid
30
Planned or actual enrollment
343

About the trial

Sponsor
AVEO Pharmaceuticals, Inc. (with Parexel, Bristol-Myers Squibb)
Tested
Tivozanib (drug), Nivolumab (drug)
Dates
Started 2021-09-09; completion 2026-01-20
Results posted
Not yet

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

From ClinicalTrials.gov, last updated 2026-05-08. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Aveo Pharmaceuticals, Inc. reported $1.6M in research payments for this study in 2025 (1,796 payments).

Products named: Fotivda

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.